Understanding INHBE: Potential Drug Target and Biomarker (G83729)

Target Name: INHBE

NCBI ID: G83729

INHBE

Understanding INHBE: Potential Drug Target and Biomarker

INHBE (inhibin beta E subunit) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key component of the INHBE complex, which is responsible for regulating the blood pressure. INHBE has been shown to have a variety of functions, including modulating blood pressure, heart rate, and blood flow.

Despite its importance, INHBE is not well understood, and its role in the body is still being explored. In this article, we will discuss the potential implications of INHBE as a drug target and biomarker, as well as its current research status and potential future directions.

Potential Drug Target

INHBE has been shown to have a variety of potential drug targets, including those related to blood pressure, heart rate, and blood flow. One of the most promising targets for INHBE is the protein GFR伪1, which is a key regulator of the GLUT-1 receptor, which is responsible for regulating the flow of blood to the body's tissues.

Research has shown that INHBE can inhibit the activity of GFR伪1, which would lead to decreased GLUT-1 receptor activity and reduced blood flow to the body's tissues. This could make INHBE a potential drug target for hypertension, heart failure, and other conditions that are related to decreased blood flow.

Biomarker

INHBE is also a potential biomarker for a variety of conditions. For example, INHBE has been shown to be downregulated in individuals with hypertension, which could be used as a diagnostic biomarker for this condition. Additionally, INHBE has been shown to be associated with an increased risk of cardiovascular disease, which could make it a useful biomarker for evaluating the effectiveness of cardiovascular interventions.

Current Research

Current research on INHBE is focused on its role in the INHBE complex and its potential drug targets. Studies have shown that INHBE plays a key role in regulating blood pressure by modulating the activity of the GLUT-1 receptor. These studies have also shown that INHBE is involved in the regulation of heart rate and blood flow, and that it is expressed in a variety of tissues throughout the body.

While there is currently little research on INHBE as a drug target or biomarker, there is potential for future studies to shed more light on its role in the body. As research continues, it is likely that we will discover new functions for INHBE and its potential as a drug or biomarker.

Conclusion

INHBE is a protein that is expressed in various tissues throughout the body and is involved in the regulation of various physiological processes, including blood pressure, heart rate, and blood flow. While its role in the body is still being explored, potential drug targets and biomarkers for INHBE are being identified, and research is ongoing to better understand its function. As research continues, it is likely that we will discover new functions for INHBE and its potential as a drug or biomarker.

Protein Name: Inhibin Subunit Beta E

Functions: Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins

The "INHBE Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INHBE comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets